^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LM-24C5

    i
    Other names: LM-24C5
    Associations

    News

    Trials
    Company:
    LaNova Medicines Limited
    Drug class:
    CD137 agonist, CEACAM5 inhibitor
    Related drugs:
    Associations

    News

    Trials
    11ms
    A Study of LM-24C5 For Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=49, Recruiting, LaNova Medicines Limited | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    LM-24C5
    11ms
    A Study of LM-24C5 For Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=49, Not yet recruiting, LaNova Medicines Limited
    New P1/2 trial • Metastases
    |
    LM-24C5
    over1year
    Pre-clinical efficacy and toxicity profile of LM-24C5: A novel CEACAM5 x 4-1BB bispecific antibody in cancer immunotherapy (AACR 2023)
    It induced superior 4-1BB activity (EC50: 1.07 nM) than benchmark antibody Urelumab (EC50: 3.38 nM) in the presence of cells expressing CEACAM5. LM-24C5 was well tolerated in hu4-1BB/4-1BBL double-transgenic mice at a dose of 100mg/kg given once weekly for 2 weeks. In summary, LM-24C5 is a novel CEACAM5 dependent 4-1BB bispecific agonist antibody that could redirect and activate T cells to CEACAM5 positive tumor cells by engaging 4-1BB antigen, thus positioned as a potential novel therapy for colorectal carcinoma and other CEACAM5 positive tumors.
    Preclinical • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule) • FCGR2A (Fc fragment of IgG receptor IIa)
    |
    CEACAM5 expression • CEACAM5 positive
    |
    LM-24C5 • urelumab (BMS-663513)